Innovative ADC Treatment Options For Cancers With a High Unmet Medical Need
Adcendo ApS is a Copenhagen-based biotech company dedicated to developing highly differentiated antibody-drug conjugates (ADCs) for the treatment of underserved cancers
What are ADCs?
Antibody-drug conjugates (ADCs) represent an emerging drug modality, directing anticancer therapeutics to malignant cells overexpressing particular surface target molecules. 10+ ADCs are now in routine clinical use for cancer patients, with many more novel ADC assets currently investigated in clinical studies in solid tumors and hematologic malignancies
The uPARAP receptor
Our name, Adcendo, reflects our aim to
develop ADCs targeting endocytic receptors overexpressed on cancer cells or on specific cells of the tumor microenvironment
About Adcendo
Adcendo was founded in 2017 as a spin-out from The University of Copenhagen and Rigshospitalet. The scientific founders, Niels Behrendt, Lars Engelholm and Christoffer Nielsen from The Finsen Laboratory, had just recently published proof-of-concept for uPARAP-directed ADCs, where a first-generation, anti-uPARAP ADC was shown to effectively mediate a curative outcome in a CDX model. Ensuring that these findings were investigated further by creating a spin-out company for this purpose, was a natural next step
Join our ambitious team
Our investors
In April 2021, Adcendo ApS closed our series A investment round at 51m EUR, though an international syndicate of leading life science and biotech investors. The round was extended in early 2023, where an additional 31m EUR was added to the series A, and the syndicate was further expanded
